IL-10 polymorphisms and prostate cancer risk: a meta-analysis

Area of Science:

• Genetics and Oncology
• Molecular Biology
• Cancer Epidemiology

Background:

• Chronic inflammation is increasingly recognized as a factor in prostate cancer (PCa) development.
• Interleukin-10 (IL-10) gene promoter polymorphisms (-1082 A>G, -819 C>T, -592 C>A) have been studied for their association with PCa risk, but findings are inconsistent.

Purpose of the Study:

• To conduct an updated meta-analysis to clarify the relationship between IL-10 gene polymorphisms and prostate cancer risk.
• To investigate the potential association of IL-10 polymorphisms with PCa aggressiveness and progression.

Main Methods:

• A comprehensive literature search identified 10 eligible studies for meta-analysis.
• Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength and precision of associations.
• Statistical analysis was performed to evaluate the overall risk and specific associations with PCa aggressiveness.

Main Results:

• No significant association was found between IL-10 -1082 A>G, -819 C>T, and -592 C>A polymorphisms and overall prostate cancer risk.
• The IL-10 -819 C>T and -592 C>A polymorphisms showed a modest association with increased PCa aggressiveness (OR=1.162, P=0.011; OR=1.131, P=0.030, respectively).
• Variant alleles at both -819 and -592 positions were modestly linked to advanced stages of prostate cancer.

Conclusions:

• IL-10 gene polymorphisms (-1082 A>G, -819 C>T, -592 C>A) do not appear to influence the overall risk of developing prostate cancer.
• Specific IL-10 polymorphisms (-819 C>T and -592 C>A) may play a role in prostate cancer aggressiveness and progression.
• Further well-designed studies are required to confirm these findings regarding the impact of IL-10 polymorphisms on PCa outcomes.